Association of Cross- Reactive Antibodies Targeting Peptidyl-Arginine Deiminase 3 and 4 with Rheumatoid Arthritis-Associated Interstitial Lung Disease

Jon T. Giles1*, Erika Darrah2, Sonye Danoff3, Cheilonda Johnson3, Felipe Andrade2, Antony Rosen2, Joan M. Bathon1

1 Division of Rheumatology, Columbia University, College of Physicians and Surgeons, New York, New York, United States of America; 2 Division of Rheumatology, Johns Hopkins University, Baltimore, Maryland, United States of America; 3 Division of Pulmonary and Critical Care Medicine, Johns Hopkins University, Baltimore, Maryland, United States of America

Abstract

Background: A subset of rheumatoid arthritis (RA) patients have detectable antibodies directed against the peptidyl-arginine deiminase (PAD) enzyme isoforms 3 and 4. Anti-PAD3/4 cross-reactive antibodies (anti-PAD3/4XR) have been shown to lower the calcium threshold required for PAD4 activation, an effect potentially relevant to the pathogenesis of RA-associated interstitial lung disease (ILD).

Methods: RA patients underwent multi-detector computed tomography (MDCT) of the chest with interpretation by a pulmonary radiologist for ILD features. A semi-quantitative ILD Score (range 0–32) was calculated. Concurrent serum samples were assessed for antibodies against PAD by immunoprecipitation with radiolabeled PAD3 and PAD4.

Results: Among the 176 RA patients studied, any ILD was observed in 58 (33%) and anti-PAD3/4XR was detected in 19 (11%). The frequency of any ILD among those with anti-PAD3/4XR was 68% vs. 29% among those with no anti-PAD (crude OR = 5.39; p = 0.002) and vs. 27% among those with anti-PAD4 that was not cross-reactive with PAD3 (crude OR = 5.74; p = 0.001). Both associations were stronger after adjustment for relevant confounders (adjusted ORs = 7.22 and 6.61, respectively; both p-values < 0.01). Among ever smokers with anti-PAD3/4XR, the adjusted frequency of any ILD was 93% vs. 17% for never smokers without the antibody (adjusted OR = 61.4; p = 0.001, p-value for the interaction of smoking with anti-PAD3/4XR < 0.05).

Conclusions: The prevalence and extent of ILD was markedly higher among RA patients with anti-PAD3/4 cross-reactive antibodies, even after accounting for relevant confounders, particularly among ever smokers. These findings may suggest etiopathologic mechanisms of RA-ILD, and their clinical utility for predicting ILD warrants additional study.

Introduction

Clinically significant interstitial lung disease (ILD) is observed in 8–15% of individuals with rheumatoid arthritis (RA) and is a major source of morbidity and mortality [1–4]. Prognosis after the development of symptomatic RA-ILD is poor, with life expectancy averaging only 2.6 years [1]. Progressive decline in lung function, supplemental oxygen requirement, physical disability, secondary pulmonary hypertension with right heart failure, and need for lung transplantation are severe consequences [4,5]. Subclinical RA-ILD is even more common, with radiographic ILD, as assessed using computed tomography (CT), observed in up to 50% of RA patients [6–8]. Although limited by the lack of clinical trials, there are, to date, no pharmacotherapies proven to be effective in altering the natural history of RA-ILD once symptoms have developed [9], and robust biomarkers for predicting those at risk for RA-ILD are lacking.

The pathogenesis of RA-ILD is poorly understood. One mechanistic possibility involves the presence and consequences of pulmonary citrullinated proteins. Citrullination is the post-
translational modification of arginine residues to citrulline catalyzed by the peptidyl-arginine deiminase (PAD) enzymes [10]. Citrullination results in a net loss of charge and a more hydrophobic protein, with implications for protein folding and tertiary structure [11,12]. Citrullinated proteins are present in lung tissue of patients with RA-ILD [13], idiopathic pulmonary fibrosis (IPF), and even broncho-alveolar lavage fluid from heavy smokers [14]. Repertoire expansion of antibodies against citrullinated protein antigens (ACPA) is associated with RA susceptibility [15], articular damage [16], and the presence and extent of radiographic RA-ILD [7], suggesting that citrullination of lung proteins and/or pathogenic ACPA may contribute to the pathogenesis of RA-ILD, perhaps via interfering with the normal functioning of targeted proteins or via pathologic antigen/antibody interactions.

PAD function is dependent on calcium, with maximal PAD function requiring 5–10 mM concentrations. This threshold is difficult to achieve in vivo and perhaps serves as a physiologic regulator of citrullination. Recently, we reported the discovery of an antibody targeting an epitope common to both PADs 3 and 4 that was highly specific for RA and was strongly associated with progression of radiographic erosions [17]. Adding purified IgG from patients with PAD3/4 cross-reactive antibodies (anti-PAD3/4XR) to PAD4 resulted in increased in vitro histone citrullination at physiologic concentrations of calcium, an effect not observed with the addition of anti-PAD4 that was not cross-reactive with PAD3.

Accordingly, we hypothesized that RA patients with anti-PAD3/4XR would demonstrate a greater prevalence and extent of RA comorbidities in which tissue citrullination and/or pathogenic ACPA may play an etiopathologic role, such as RA-ILD.

Methods

Study Participants

Participants were enrolled in ESCAPE RA (Evaluation of Subclinical Cardiovascular disease And Predictors of Events in Rheumatoid Arthritis), a prospective cohort study investigating subclinical cardiovascular disease in RA described previously [18,19]. Participants met 1987 RA classification criteria [20], had RA ≥6 months from diagnosis, and were 45–84 years of age without known prior pre-specified cardiovascular events. All participants provided written informed consent prior to enrollment, and the study and consent procedures were approved by the Institutional Review Board (IRB) of the Johns Hopkins Hospital. Ongoing analyses were approved by the Columbia University Medical Center IRB. Enrollment occurred between October 2004 and May 2006.

Outcomes

Pulmonary outcomes. As described previously [18], cardiac multi-detector row CT (MDCT) scans were obtained using standard methods [21] with 3 mm thickness on a Toshiba Aquilion 64 scanner. With cardiac MDCT, only lung parenchyma from the level of the carina to the lung bases was included. The validity of cardiac MDCT for pulmonary parenchymal disease has been evaluated, with correlation >90% compared to high-resolution CT [22]. Scans were assessable in 176 of the 195 enrolled participants (91%) by an expert pulmonary radiologist using a previously described standardized method [23] and blinded to clinical characteristics. Characteristics of the subgroup with assessable scans did not differ from those of the full cohort (data not shown). An ILD score (ILDS) was calculated based on the presence and extent of ILD features [i.e. ground glass opacification (GGO), reticulation (R), honeycombing (HC), and traction bronchiectasis (TB)] using a semi-quantitative scale (0 = none, 1 = 1–25%, 2 = 26–50%, 3 = 51–75%, 4 = 76–100%) with a maximum total score possible of 32. Intra-observer concordance for detecting no ILD was 90%, and 100% for ILDS ≥3. Pulmonary function testing (PFT), consisting of spirometry and assessment of carbon monoxide diffusing capacity (DLCo), was performed according to American Thoracic Society guidelines [24] at the second study visit, occurring a mean ± standard deviation of 21 ± 3 months post-baseline. Any restriction and impaired diffusion were both defined as ≥59% of predicted for forced vital capacity (FVC) and DLCo, respectively.

Measurement of circulating anti-PAD3/4XR. Antibodies against PADs 3 and 4 were assessed as previously described [17]. Briefly, patient serum was added to [135S]Methionine labeled in vitro transcribed and translated PAD3 or PAD4. Radioimmunoprecipitated immune complexes were incubated with Protein A beads and subsequently washed and boiled in SDS sample buffer. Radiography was used to visualize immunoprecipitated proteins separated by gel electrophoresis. Proteins were quantified using densitometry and levels normalized a standard sample with the high titer anti-PAD3/4XR antibodies. Seropositivity was defined as ≥0.01 of the normalized value, as none of the non-RA control samples (from healthy controls and patients with psoriatic arthritis) had levels above this cutpoint [17].

Other measures. Demographics, current and past smoking, and medical and RA disease history were assessed by patient self-report. Forty-four joints were examined for swelling and tenderness by a single trained assessor and RA disease activity calculated using the Disease Activity Score for 28 joints with CRP (DAS28-CRP) [25]. The Stanford Health Assessment Questionnaire (HAQ) [26] was used to assess disability. Current and past use of glucocorticoids, biologic and non-biologic disease modifying anti-rheumatic drugs (DMARDs) was queried by detailed examiner-administered questionnaires. Radiographs of the hands and feet were scored using the van der Heijde modification of the Sharp method (SHS) [27] by a single experienced reader blinded to patient characteristics.

Other laboratory assessments. C-reactive protein (CRP) was measured by nephelometry (Dade Behring Inc., Deerfield, IL). RF was assessed by ELISA, with seropositivity defined at or above a level of 40 units. Serum samples obtained concurrently with CT scanning were assessed for anti-CCP antibodies (CCP2) using a commercial kit. The presence of shared epitope alleles in exon 2 of HLA-DRB1 was determined as previously described [19].

Statistical Methods

After exploring the distributions of all variables, group-wise differences in normally distributed continuous variables were compared using t-tests, in non-normally distributed continuous variables using the Kruskal-Wallis test, and in categorical variables using the chi-square goodness-of-fit or Fisher’s exact test, as appropriate. The associations of PAD antibody status with dichotomous pulmonary outcomes were explored using ordinary logistic regression, and for continuous pulmonary outcomes with linear regression, with variables transformed to normality as required. Multivariable (MV) regression models were constructed, with potential confounders included that were associated with the primary exposure variable in univariate analyses at the p < 0.20 significance level, to allow for residual confounding. Non-contributory covariates were excluded using the Likelihood-Ratio Test for nested models or Akaike’s Information Criterion, as appropriate. Variance inflation factors were calculated to ensure that collinear covariates were not coodeled. All calculations were performed using Intercooled Stata 12 (StataCorp, College Station, TX). A two-tailed α of 0.05 was used throughout.
Results

Among the 176 RA participants with interpretable lung CT scans, 56 (32%) had antibodies against PAD4; however, only 19 (11%) had anti-PAD3/4XR. Participant characteristics according to antibody status are summarized in Table 1. Compared with individuals negative for anti-PAD, those with anti-PAD3/4XR were slightly older and less likely to be a current smoker, with trends to significance for both. Those with anti-PAD3/4XR had a median disease duration 13 years greater than those with no anti-PAD (p<0.001) and were significantly more likely to be seropositive for RF or CCP2 compared with both the groups with no anti-PAD and those with anti-PAD4 not cross-reactive with PAD3, although associations with the individual autoantibodies were not as strong. As previously published [17], those with anti-PAD3/4XR had a median disease duration 13 years greater than those with no anti-PAD (p<0.001) and were significantly more likely to be seropositive for RF or CCP2 compared with both the groups with no anti-PAD and the group with anti-PAD4 that did not cross-react with PAD3 (both comparisons p<0.05). The prevalence of both GGO and R/TB/HC was also higher among those with anti-PAD3/4XR compared with the other antibody groups. However, anti-PAD3/4XR was not associated with RA disease activity measures or treatments.

Anti-PAD3/4XR was Associated with CT-ILD in Unadjusted Analyses

Pulmonary outcomes according to antibody status are summarized in Table 2. Any ILD was observed in 58 participants (33%), among whom 22 (38%) demonstrated a predominant radiographic ILD pattern of GGO and 36 (62%) demonstrated R/TB/HC. The median ILD score was 0, with a range of 0–10 units. The median emphysema score was also 0, and ranged from 0–6. Among the 158 patients with PFTs, 44 (28%) had any abnormality, with 30 (21%) demonstrating restriction or impaired diffusion. Among the 168 patients with assessment of respiratory symptoms, 69 (41%) reported any symptoms, with a median number of symptoms of 0 (range 0–4).

For univariate comparisons of pulmonary outcomes according to antibody status, the prevalence of any ILD was more than double among those with anti-PAD3/4XR compared with the group with no anti-PAD and the group with anti-PAD4 that did not cross-react with PAD3 (both comparisons p<0.05). The prevalence of both GGO and R/TB/HC was also higher among those with anti-PAD3/4XR compared with the other antibody groups. However, anti-PAD3/4XR was not associated with PFT abnormalities, nor the presence or number of respiratory symptoms.

RA Characteristics were Associated with Radiographic ILD

The associations of participant characteristics with the presence of any ILD features on CT (i.e. an ILD score $.0$) are summarized in Table 1. Patient Characteristics According to PAD3/4 Cross-Reactive Antibody Status.

| Characteristic                  | Total (n = 176) | No anti-PAD (n = 120) | Anti-PAD4 only (n = 37) | Anti-PAD3/4XR (n = 19) | p-value*  |
|---------------------------------|----------------|-----------------------|-------------------------|------------------------|-----------|
| Age, years                      | 59±9           | 59±8                  | 58±9                    | 62±7                   | 0.093     |
| Male, n (%)                     | 71 (40)        | 43 (36)               | 21 (57)                 | 8 (42)                 | 0.60      |
| White, n (%)                    | 152 (86)       | 101 (84)              | 35 (95)                 | 16 (84)                | 0.99      |
| Any college, n (%)              | 133 (76)       | 86 (72)               | 31 (84)                 | 16 (84)                | 0.25      |
| Ever smoking, n (%)             | 105 (60)       | 80 (67)               | 16 (43)                 | 10 (53)                | 0.23      |
| Current smoking, n (%)          | 20 (11)        | 19 (16)               | 2 (5)                   | 0 (0)                  | 0.075     |
| Reported lung disease (n = 168), n (%) | 27 (16) | 22 (19)               | 4 (12)                  | 1 (6)                  | 0.30      |
| RA duration, years              | 8 (4–17)       | 7 (4–12)              | 15 (7–23)               | 20 (11–28)             | <0.001    |
| RF or CCP2 seropositivity, n (%)| 137 (78)       | 87 (73)               | 33 (89)                 | 18 (95)                | 0.043     |
| RF seropositivity, n (%)        | 114 (65)       | 73 (61)               | 26 (70)                 | 15 (79)                | 0.20      |
| CCP2 seropositivity, n (%)      | 122 (70)       | 76 (64)               | 31 (84)                 | 15 (79)                | 0.30      |
| Any shared epitope alleles, n (%)| 122 (70)      | 79 (67)               | 30 (81)                 | 14 (74)                | 0.79      |
| DAS28-CRP                       | 3.7 (2.9–4.4)  | 3.6 (2.9–4.3)         | 3.5 (2.8–4.5)           | 3.8 (3.3–4.3)          | 0.68      |
| CRP, mg/L                       | 2.4 (1.1–7.7)  | 2.1 (1.0–7.1)         | 3.5 (1.5–9.5)           | 2.0 (1.6–5.4)          | 0.65      |
| IL-6, pg/mL                     | 3.7 (1.8–7.8)  | 3.6 (1.7–8.1)         | 3.9 (1.8–6.3)           | 3.7 (2.4–9.0)          | 0.24      |
| Total SHS                       | 8 (1–37)       | 5 (0–19)              | 12 (2–43)               | 56 (14–132)            | <0.001    |
| Pain (100 mm VAS)               | 21 (9–41)      | 21 (8–40)             | 23 (10–41)              | 20 (5–47)              | 0.71      |
| HAQ-DI (0–3)                    | 0.63 (0.12–1.25)| 0.63 (0.12–1.25) | 0.75 (0.12–1.25)        | 0.75 (0.1–1.88)        | 0.71      |
| Current prednisone, n (%)       | 67 (38)        | 45 (38)               | 13 (35)                 | 9 (47)                 | 0.41      |
| Current non-biologic DMARDs, n (%)| 150 (86)   | 100 (84)              | 34 (92)                 | 16 (84)                | 0.99      |
| Methotrexate, n (%)             | 114 (65)       | 79 (66)               | 22 (59)                 | 13 (68)                | 0.83      |
| Leflunomide, n (%)              | 19 (11)        | 11 (9)                | 5 (14)                  | 3 (16)                 | 0.41      |
| Current biologic DMARDs, n (%)  | 81 (46)        | 55 (46)               | 17 (46)                 | 10 (53)                | 0.63      |
| TNF inhibitors, n (%)           | 78 (45)        | 52 (44)               | 17 (46)                 | 10 (53)                | 0.62      |
| Number of failed DMARDs         | 1 (0–2)        | 1 (0–2)               | 1 (0–3)                 | 2 (0–2)                | 0.75      |

Values are mean ± standard deviation or median (interquartile range) unless otherwise noted. *p-values are for the comparison of the no anti-PAD vs. anti-PAD3/4XR groups.

P = 0.05; PAD3/4 = anti-PAD3/4 Cross-Reactive antibodies; RA = rheumatoid arthritis; RF = rheumatoid factor; CCP2 = 2nd generation anti-cyclic citrullinated peptide antibody; DAS = disease activity score; CRP = C-reactive protein; IL = interleukin; SHS = Total modified Sharp-van der Heijde Score; HAQ = Health Assessment Questionnaire Disability Index; TNF = tumor necrosis factor; DMARD = disease modifying anti-rheumatic drug.

doi:10.1371/journal.pone.0098794.t001
The etiopathology of RA-ILD is poorly understood. Adding to the complexity is heterogeneity in ILD histopathology and the high prevalence of asymptomatic disease [6]. However, in the setting of clinical symptoms the disease can be a severe and frequently lethal consequence of RA [1,4]. Citrullination of lung surface proteins may contribute to the pathogenesis of RA-ILD. Fibroblast and lymphocyte migration through the pulmonary extracellular matrix to areas of damage, as well as cellular differentiation and activation, are dependent on interactions between matrix and cell surface proteins that are highly regulated [28–30]. Citrullination of key matrix proteins, therefore, could result in aberrant cellular migration, differentiation, and activation resulting in abnormal

### Table 2. Pulmonary Outcomes According to PAD3/4 Cross-Reactive Antibody Status.

| Characteristic                  | Total (n = 176) | No anti-PAD (n = 120) | Anti-PAD4 only (n = 37) | Anti-PAD3/4XR (n = 19) | p-value* |
|--------------------------------|----------------|-----------------------|------------------------|------------------------|----------|
| Any ILD, n (%)                 | 58 (33)        | 35 (29)               | 10 (27)                | 13 (68)                | 0.001    |
| Any GGO, n (%)                 | 22 (13)        | 11 (10)               | 6 (16)                 | 5 (28)                 | 0.047    |
| Any R/TB/HC, n (%)             | 36 (22)        | 21 (19)               | 8 (22)                 | 7 (39)                 | 0.045    |
| ILD Score, units (0–32)        | 0 (0–2; range 0–10) | 0 (0–2; range 0–6) | 0 (0–2; range 0–10) | 2 (0–2; range 0–10) | 0.020    |
| Emphysema score, units (0–32)  | 0 (0–0; range 0–6) | 0 (0–0; range 0–6) | 0 (0–0; range 0–4) | 0 (0–0; range 0–2) | 0.77     |
| Any PFT Abnormality (n = 158), n (%) | 44 (28)       | 33 (29)               | 9 (29)                 | 2 (13)                 | 0.23     |
| Any PFT Restriction or Impaired Diffusion, n (%) | 30 (21)       | 21 (22)               | 8 (27)                 | 1 (8)                  | 0.46     |
| Any respiratory symptoms (n = 168), n (%) | 69 (41)       | 47 (40)               | 13 (38)               | 9 (53)                 | 0.43     |
| Number of respiratory symptoms (n = 168) | 0 (0–1; range 0–4) | 0 (0–1; range 0–4) | 0 (0–2; range 0–4) | 1 (0–1; range 0–3) | 0.55     |

Values are median (interquartile range) unless otherwise noted.

*p-values are for the comparison of the no anti-PAD vs. anti-PAD3/4XR groups.

PAD = peptidyl-arginine deiminase; anti-PAD3/4XR = anti-PAD3/4 Cross-Reactive antibodies; RA = rheumatoid arthritis; ILD = interstitial lung disease; GGO = ground glass opacification; R/TB/HC = reticulation/traction bronchiectasis/honeycombing; PFT = pulmonary function testing; Impaired Diff = impaired diffusion.

doi:10.1371/journal.pone.0098794.t002

in Table 3. Those with any ILD features on CT tended to be older than those without ILD and were more likely to be male (both with trends to significance). Any ILD was strongly associated with both current and past smoking, but not with reported lung disease. Those with any ILD were significantly more likely to be treated with prednisone and HAQ among those with vs. without ILD. Those with ILD were also significantly more likely to be treated with prednisone or leflunomide use, or the number of failed DMARDs. As expected, those with ILD were significantly more likely to have PFT restriction or impaired diffusion and report respiratory symptoms compared with those without ILD.

### Anti-PAD3/4XR Remained Associated with Any ILD After Adjustment

Crude and adjusted associations of anti-PAD3/4XR with pulmonary outcomes are summarized in Figure 1. After adjusting for characteristics associated with either anti-PAD3/4XR or any ILD, anti-PAD3/4XR remained significantly associated with any ILD compared with those with no anti-PAD or those with anti-PAD4 that did not cross-react with PAD3 (adjusted OR = 7.22 for the comparison of anti-PAD3/4XR vs. no anti-PAD; p = 0.001).

The combination of anti-PAD3/4XR with smoking was highly associated with any ILD features.

The individual and combined associations of anti-PAD3/4XR and ever smoking with any ILD are depicted in Figure 2. Before adjustment, only 16% of participants who were anti-PAD3/4XR negative and had never smoked had any ILD features on CT. The prevalence of any ILD was higher among those with either characteristic, and the magnitude of the association was similar for never smokers with anti-PAD3/4XR vs. ever smokers without the antibody. However, 90% of ever smokers seropositive for anti-PAD3/4XR demonstrated any features of ILD. The prevalence remained significantly higher for this group compared with the other groups after adjustment, resulting in an adjusted OR of 61.4 for the comparison of any ILD for ever smokers with anti-PAD3/4XR compared with never smokers without the antibody (p = 0.001).

### Adjusted Associations of PAD3/4XR with Other Pulmonary Outcomes

Associations of anti-PAD3/4XR with other pulmonary outcomes are summarized in Table 4. Both GGO and R/TB/HC were significantly higher among RA patients with anti-PAD3/4XR compared to those negative for the antibody in unadjusted analyses. However, only the predominant pattern of GGO was significantly associated after MV adjustment. Additionally after MV adjustment, anti-PAD3/4XR was associated with a higher ILD Score when considered as a continuous variable. However, anti-PAD3/4XR was not associated with any abnormalities on PFTs or the presence or number of reported respiratory symptoms in either crude or adjusted analyses.

### Discussion

In this first investigation of the relationship between the recently discovered RA-specific auto-antibody, anti-PAD3/4XR, and radiographic ILD, we detected a robust association for both the presence and extent of RA-ILD among patients with anti-PAD3/4XR compared with patients with no anti-PAD antibodies and even among those with anti-PAD4 antibodies that did not cross-react with PAD3. The associations were not diminished in magnitude under various relevant MV adjustment scenarios. Notably, the combination of anti-PAD3/4XR with a history of smoking was particularly robust in its association with RA-ILD, with a synergistic interaction suggested.
tissue repair, ectopic fibrosis, and dysregulated inflammation. For example, attachment and spreading of fibroblasts was impaired on plates coated with citrullinated fibronectin compared with non-citrullinated fibronectin [31]. This mechanism may not be exclusive to RA, as the presence of citrullinated proteins has been detected in the tissue targets of several autoimmune conditions, including the lungs of non-RA patients with ILD [13,14]. An additional possibility is that citrullinated proteins in the lung are targets for ACPA, an interaction that may drive ILD. This possibility is supported by recent evidence for the presence of ACPA in the sputum of RA patients [32]. However, at present, any speculative mechanistic links between citrullinated proteins in the lung, ACPA generation and pathogenesis, and ILD remain to be elucidated.

While citrullination of lung proteins may contribute to the pathogenesis of ILD, physiologic barriers limiting PAD activity may have evolved to regulate such pathologic citrullination. For one, the calcium threshold for PAD catalytic activity typically use 5–10 mM calcium concentrations for maximal PAD activity, whereas in vitro extra-cellular levels typically do not exceed 1.5 mM [33]. Recently [17], we showed that anti-PAD3/4XR antibodies increased the sensitivity of PAD4 to calcium allowing efficient citrullination in the context of physiologic calcium concentrations. From the same report, anti-PAD3/4XR reacted with PAD4 at a key calcium binding site that is also involved in protein-protein interactions, suggesting that the antibody may create a permissive environment for calcium activated catalysis. Therefore, the analyses presented here provide a circumstantial link between a disease manifestation in which aberrant citrullination may play a pathogenic role (i.e. ILD) and the mechanism by which citrullination may be facilitated (i.e. anti-PAD3/4XR).

Smoking is a well-established risk factor for both RA [34] and ILD [35], and, as confirmed among the cohort reported here, RA patients with a history of smoking were more likely to have radiographic ILD. Additionally, compared with non-smokers, smokers had higher levels of PAD2 in the bronchial mucosa, but

**Table 3.** Patient Characteristics According to the Presence of CT-ILD Features.

| Characteristic                  | No ILD (n = 118) | Any ILD (n = 58) | p-value |
|--------------------------------|-----------------|-----------------|---------|
| Age, years                     | 58±8            | 61±9            | 0.071   |
| Male, n (%)                    | 43 (36)         | 29 (50)         | 0.085   |
| White, n (%)                   | 101 (86)        | 51 (88)         | 0.67    |
| Any college, n (%)             | 87 (74)         | 46 (79)         | 0.42    |
| Ever smoking, n (%)            | 62 (53)         | 44 (76)         | 0.003   |
| Current smoking, n (%)         | 7 (6)           | 14 (24)         | <0.001  |
| Reported lung disease (n = 168), n (%) | 19 (17)     | 8 (14)          | 0.66    |
| RA duration, years             | 8 (4–16)        | 8 (5–19)        | 0.22    |
| RF or CCP2 seropositivity, n (%) | 86 (73)     | 52 (90)         | 0.11    |
| RF seropositivity, n (%)       | 71 (60)         | 43 (75)         | 0.047   |
| CCP2 seropositivity, n (%)     | 73 (62)         | 49 (86)         | 0.001   |
| Any shared epitope alleles, n (%) | 80 (68)   | 43 (75)         | 0.34    |
| DAS28-CRP                      | 3.5 (2.8–4.3)   | 3.8 (3.2–4.5)   | 0.12    |
| CRP, mg/L                      | 2.3 (1.0–7.2)   | 3.5 (1.2–9.3)   | 0.58    |
| IL-6, pg/mL                    | 3.0 (1.6–7.0)   | 4.5 (2.3–9.5)   | 0.029   |
| Total SHS                      | 6 (0–26)        | 12 (2–55)       | 0.074   |
| Pain (100 mm VAS)              | 19 (10–40)      | 24 (8–47)       | 0.52    |
| HAQ-DI (0–3)                   | 0.62 (0.12–1.25)| 0.75 (0.25–1.50)| 0.083   |
| Current prednisone, n (%)      | 37 (31)         | 30 (52)         | 0.009   |
| Current non-biologic DMARDs, n (%) | 103 (88)   | 47 (81)         | 0.21    |
| Methotrexate, n (%)            | 81 (69)         | 33 (57)         | 0.13    |
| Leflunomide, n (%)             | 11 (9)          | 8 (14)          | 0.37    |
| Current biologic DMARDs, n (%) | 48 (41)         | 34 (59)         | 0.028   |
| TNF inhibitors, n (%)          | 46 (39)         | 33 (57)         | 0.028   |
| Number of failed DMARDs        | 1 (0–2)         | 1 (0–2)         | 0.80    |
| Any PFT Abnormality (n = 158), n (%) | 22 (21)    | 22 (43)         | 0.003   |
| Any PFT Restriction or Impaired Diffusion, n (%) | 12 (13)       | 18 (41)         | <0.001  |
| Any respiratory symptoms (n = 168), n (%) | 40 (38)    | 29 (52)         | 0.046   |
| Number of respiratory symptoms | 0 (0–1)        | 1 (0–2)         | 0.017   |

Values are mean ± standard deviation or median (interquartile range) unless otherwise noted. RA = rheumatoid arthritis; RF = rheumatoid factor; CCP2 = 2nd generation anti-cyclic citrullinated peptide antibody; DAS = disease activity score; CRP = C-reactive protein; IL = interleukin; SHS = Total modified Sharp-van der Heijde Score; HAQ = Health Assessment Questionnaire Disability Index; TNF = tumor necrosis factor; DMARD = disease modifying anti-rheumatic drug; ILD = interstitial lung disease; PFT = pulmonary function testing; Impaired Diff = impaired diffusion. doi:10.1371/journal.pone.0098794.t003
no difference in the amount of protein citrullination in the same tissue [14]. In our study, the combined effect of smoking plus anti-PAD3/4XR was greater than the sum of the individual effects of either characteristic in isolation, suggesting a possible synergistic interaction. In this setting, PAD up-regulation conferred by smoking combined with the enhanced catalytic activity of PAD4 conferred by anti-PAD3/4XR could provide the stimulus for the enhanced pathogenic effect observed. Based on this circumstantial evidence, testing of this speculative mechanistic hypothesis is warranted.

The study has notable strengths and limitations. Among the strengths, scans were interpreted by the same pulmonary radiologist with decades of ILD experience, and ILD features correlated with both PFT abnormalities and respiratory symptoms. Among the limitations, cardiac MDCT differs from high-resolution CT (HRCT) in slice thickness and the lung apices were not imaged. However, while we may have missed additional ILD features exclusive to the apices (uncommon for RA-ILD), our findings are internally consistent since the same techniques were used for all patients. Owing to the characteristics of the cohort, our findings may only be generalizable to RA patients 45 years of age without prior cardiovascular events, and, notably, there were few patients with severe RA-ILD included. Additionally, the primary comparisons were cross-sectional, limiting any ability to establish temporality in the associations. Additional longitudinal work is underway exploring the temporal relationship between emergence of anti-PAD3/4XR over the time-course of RA and incident RA-ILD.

In summary, anti-PAD3/4XR seropositivity was detected in a subset of RA patients with longer standing, seropositive, destructive disease. Independent of these features, the presence of anti-PAD3/4XR remained highly associated with the presence and extent of ILD, assessed by CT scanning. Interestingly, the
We are indebted to the dedication and hard work of the ESCAPE RA Staff: Marilyn Towns, Michelle Jones, Patricia Jones, Marisa Hildebrandt, Shawn Franckowiak, and Brandy Miles and to the participants of the ESCAPE RA study who graciously agreed to take part in this research. Drs. Uzma Haque, Clifton Bingham III, Carol Ziminski, Jill Ratam, Ira Fine, Joyce Mofficky-Burd, David McGinnis, Andrea Marx, Howard Hauptman, Achini Perera, Peter Holt, Alan Matsumoto, Megan Clowse, Gordon Lam and others generously recommended their patients for this study.

Author Contributions
Conceived and designed the experiments: JTG ED SD CJ FA AR JMB. Performed the experiments: ED FA AR. Analyzed the data: JTG. Contributed reagents/materials/analysis tools: ED FA AR JTG. Wrote the paper: JTG ED SD CJ FA AR JMB.

Table 4. Crude and Adjusted Associations of PAD3/4 Cross-Reactive Antibodies with Pulmonary Outcomes in RA.

| Outcome                        | Crude  | Adjusted* | Adjusted** |
|--------------------------------|--------|-----------|------------|
|                                | β      | p-value   | β          | p-value   | β          | p-value   |
| Any ILD†                        | 5.39   | 0.001     | 4.37       | 0.011     | 7.22       | 0.001     |
| Any GGO‡                        | 2.99   | 0.042     | 3.93       | 0.034     | 3.50       | 0.043     |
| Any R/TB/HC§                     | 2.63   | 0.046     | 1.13       | 0.85      | 2.10       | 0.22      |
| Any PFT Abnormality†            | 0.51   | 0.30      | 0.37       | 0.15      | 0.45       | 0.25      |
| Any PFT Restriction or Impaired Diff† | 0.48   | 0.36      | 0.40       | 0.26      | 0.59       | 0.52      |
| Any respiratory symptoms†      | 1.81   | 0.22      | 1.74       | 0.29      | 2.15       | 0.17      |
| Square root ILD Score           | 0.61   | 0.004     | 0.52       | 0.022     | 0.61       | 0.002     |

*Adjusted for age, gender, RF, CCP2, RA duration, DAS28, prednisone use, biologic DMARD use, current and past smoking, and SHS.
**Adjusted for age, gender, RF, CCP2, RA duration, DAS28, prednisone use, biologic DMARD use, current and past smoking, and SHS.
†ILD = interstitial lung disease; GGO = ground glass opacification; R/TB/HC = reticulation/traction bronchiectasis/honeycombing; PFT = pulmonary function testing; Impaired Diff = impaired diffusion; RA = rheumatoid arthritis; RF = rheumatoid factor; CCP2 = 2nd generation anti-cyclic citrullinated peptide antibody; DAS = disease activity score; CRP = C-reactive protein; IL = interleukin; SHS = Total modified Sharp-van der Heijde Score; DMARD = disease modifying anti-rheumatic drug.

References
1. Bongartz T, Naunini C, Medina-Velasquez YF, Achenbach SJ, Crowthorn CS, et al. (2010) Incidence and mortality of interstitial lung disease in rheumatoid arthritis: a population-based study. Arthritis and Rheumatism 62: 1583–1591.
2. Koduri G, Norton S, Young A, Cox N, Davies P, et al. (2010) Interstitial lung disease has a poor prognosis in rheumatoid arthritis: results from an inception cohort. Rheumatology (Oxford) 49: 1483–1489.
3. Young A, Koduri G, Batley M, Kalinska E, Gough A, et al. (2007) Mortality in rheumatoid arthritis. Increased in the early course of disease, in ischaemic heart disease and in pulmonary fibrosis. Rheumatology (Oxford) 46: 330–337.
4. Olson AL, Swigris JJ, Sprunger DB, Fischer A, Fernandez-Perez ER, et al. (2011) Rheumatoid arthritis-interstitial lung disease-associated mortality. American journal of respiratory and critical care medicine 183: 372–378.
5. Solomon JJ, Ruy JJ, Tzavela HD, Myers JL, Tudor R, et al. (2013) Fibrosing interstitial pneumonia predicts survival in patients with rheumatoid arthritis-associated interstitial lung disease (RA-ILD). Respir Med 107: 1247–1252.
6. Dawson JK, Fewins HE, Desmond J, Lynch MP, Graham DR (2001) Fibrosing alveolitis in patients with rheumatoid arthritis as assessed by high resolution computed tomography, chest radiography, and pulmonary function tests. Thorax 56: 622–627.
7. Giles JT, Danoff SK, Sokolove J, Wagner CA, Winchester R, et al. (2013) Association of fine specificity and repertoire expansion of anticitrullinated peptide antibodies with rheumatoid arthritis associated interstitial lung disease. Ann Rheum Dis doi:10.1136.
8. McDonough J, Greaves M, Wright AR, Heycock C, Owen JP, et al. (1994) High resolution computed tomography of the lungs in patients with rheumatoid arthritis and interstitial lung disease. Br J Rheumatism 33: 118–122.
9. Vij R, Strek ME (2013) Diagnosis and treatment of connective tissue disease-associated interstitial lung disease. Chest 143: 814–824.
10. Vossenaar ER, Zemden AJ, van Vrentsj MJ, Prijijn GJ (2003) PAD, a growing family of citrullinating enzymes: genes, features and involvement in disease. BioEssays: news and reviews in molecular, cellular and developmental biology 25: 1106–1118.
11. Ordonez A, Martinez-Martinez I, Corrales EJ, Miqueo C, Minano A, et al. (2009) Effect of citrullination on the function and conformation of antithrombin. FEBS J 276: 6763–6772.
12. Mortier A, Loos T, Gorney M, Korne L, Van Damme J, et al. (2010) Posttranslational modification of the NH2-terminal region of CXCL5 by proteases or peptidylarginine Deiminases (PAD) differently affects its biological activity. J Biol Chem 285: 29750–29759.
13. Bongartz T, Cantaert T, Atkins SR, Harle P, Myers JI, et al. (2007) Citrullination in extra-articular manifestations of rheumatoid arthritis. Rheumatology (Oxford, England) 46: 70–75.
14. Makryianakis D, Herrmanns M, Uflgren AK, Nicholas AP, Zedman AJ, et al. (2006) Smoking increases peptidylarginine deiminase 2 enzyme expression in human lungs and increases citrullination in BAL cells. 67: 1488–1492.
15. Sokolove J, Beomboong R, Deane KD, Lahey LJ, Derber LA, et al. (2012) Autoantibody epitope spreading in the pre-clinical phase predicts progression to rheumatoid arthritis. PLoS one 7: e52986.
16. van Gaalen FA, van Aken J, Huizinga TW, Schreuder GM, Breedveld FC, et al. (2004) Association between HLA class II genes and autoantinibodies to cyclic citrullinated peptides (CCPs) influences the severity of rheumatoid arthritis. Arthritis and Rheumatism 50: 2113–2121.
17. Darrah E, Giles JT, Ols ML, Bull HG, Andrade F, et al. (2013) Erosive rheumatoid arthritis is associated with antibodies that activate PAD4 by increasing calcium sensitivity. Sci Transl Med 5: 186ra165.
18. Giles JT, Saldin M, Post W, Petri M, Blumenhalh RS, et al. (2009) Coronary arterial calcification in rheumatoid arthritis: comparison to the multi-ethnic study of atherosclerosis. Arthritis research & therapy 11: R36.
19. Kobayashi H, Giles JT, Polak JP, Blumenhalh RS, Leffell MS, et al. (2010) Increased prevalence of carotid artery atherosclerosis in rheumatoid arthritis is artery-specific. The Journal of rheumatology 37: 730–739.
20. Arnett FC, Echoworthy SM, Bloch DA, McShane DJ, Fries JF, et al. (1988) The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis and Rheumatism 31: 315–324.
21. Carr JJ, Nelson JC, Wong ND, McNitt-Gray M, Arad Y, et al. (2005) Calcified coronary artery plaque measurement with cardiac CT in population-based studies: standardized protocol of Multi-Ethnic Study of Atherosclerosis (MESA) and Coronary Artery Risk Development in Young Adults (CARDIA) study. Radiology 234: 35–43.

22. Hoffman EA, Jiang R, Baumhauer H, Brooks MA, Carr JJ, et al. (2009) Reproducibility and validity of lung density measures from cardiac CT scans–The Multi-Ethnic Study of Atherosclerosis (MESA) Lung Study. Academic Radiology 16: 689–699.

23. Goldin JG, Lynch DA, Strollo DC, Suh RD, Schraufnagel DE, et al. (2008) High-resolution CT scan findings in patients with symptomatic scleroderma-related interstitial lung disease. Chest 134: 358–367.

24. Miller MR, Crapo R, Hankinson J, Brusasco V, Burgos F, et al. (2005) General considerations for lung function testing. The European respiratory journal: official journal of the European Society for Clinical Respiratory Physiology 26: 153–161.

25. Prevoo ML, van ‘t Hof MA, Kuper HH, van Leeuwen MA, van de Putte LB, et al. (1995) Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis and Rheumatism 38: 44–48.

26. Wolfe F, Kleinheksel SM, Cathey MA, Hawley DJ, Spitz PW, et al. (1988) The clinical value of the Stanford Health Assessment Questionnaire Functional Disability Index in patients with rheumatoid arthritis. The Journal of rheumatology 15: 1480–1488.

27. van der Heijde D (2000) How to read radiographs according to the Sharp/van der Heijde method. The Journal of rheumatology 27: 261–263.

28. Felsenfeld DP, Choquet D, Sheetz MP (1996) Ligand binding regulates the directed movement of beta1 integrins on fibroblasts. Nature 383: 435–440.

29. Sheetz MP, Felsenfeld DP, Gallbraith CG (1998) Cell migration: regulation of force on extracellular-matrix-integrin complexes. Trends Cell Biol 8: 51–54.

30. Luzina IG, Todd NW, Nacci N, Lockenrath V, Chou J, et al. (2009) Regulation of pulmonary inflammation and fibrosis through expression of integrins alphaVbeta3 and alphaVbeta5 on pulmonary T lymphocytes. Arthritis Rheum 60: 1530–1539.

31. Shelef MA, Bennin DA, Mosher DF, Hutterlocher A (2012) Citrullination of fibronectin modulates synovial fibroblast behavior. Arthritis Res Ther 14: R240.

32. Willis VC, Demourelle MK, Derber LA, Chartier-Logan CJ, Parish MC, et al. (2013) Sputum autoantibodies in patients with established rheumatoid arthritis and subjects at risk of future clinically apparent disease. Arthritis Rheum 65: 2545–2554.

33. Robertson WG, Marshall RW (1981) Ionized calcium in body fluids. Crit Rev Clin Lab Sci 15: 85–125.

34. Kallberg H, Ding B, Padyukov L, Bengtsson C, Ronnelid J, et al. (2011) Smoking is a major preventable risk factor for rheumatoid arthritis: estimations of risks after various exposures to cigarette smoke. Annals of the Rheumatic Diseases 70: 508–511.

35. Baumgartner KB, Samet JM, Couthas DE, Stidley CA, Hunt WC, et al. (2000) Occupational and environmental risk factors for idiopathic pulmonary fibrosis: a multicenter case-control study. Collaborating Centers. American Journal of Epidemiology 152: 307–315.